Vertex Pharmaceuticals (VRTX +1.4%) gains after announcing earlier that the Health Service Executive in the Republic of Ireland will fund Kalydeco. The drug is the first to treat the underlying cause of cystic fibrosis for people ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene, and helps the defective protein function more normally.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs